###begin article-title 0
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 22 27 22 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
Rad9 modulates the P21WAF1 pathway by direct association with p53
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 285 288 285 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</italic>
###xml 288 292 288 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1</italic></sup>
###xml 450 453 450 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1</italic>
###xml 453 457 453 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1</italic></sup>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Previous studies suggest that human RAD9 (hRad9), encoding a DNA damage checkpoint molecule, which is frequently amplified in epithelial tumor cells of breast, lung, head and neck cancer, participates in regulation of the tumor suppressor p53-dependent transactivation of pro-survival P21WAF1. This study examined the exact mechanism of the hRad9 function, especially through the phosphorylation of the C-terminus, in the transcription regulation of P21WAF1.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 120 125 120 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 196 201 196 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
###xml 388 391 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 391 396 391 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
The transfection of phosphorylation-defective hRAD9 mutants of C-terminus resulted in reduction of the p53-dependent P21WAF1 transactivation; the knockdown of total hRad9 elicited an increased P21WAF1 mRNA expression. Immunoprecipitation and a ChIP assay showed that hRad9 and p53 formed a complex and both were associated with two p53-consensus DNA-binding sequences in the 5' region of P21WAF1 gene. The association was reduced in the experiment of phosphorylation-defective hRAD9 mutants.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WAF1 </italic>
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WAF1 </italic></sup>
The present study indicates the direct involvement of hRad9 in the p53-dependent P21WAF1 transcriptional mechanism, presumably via the phosphorylation sites, and alterations of the hRad9 pathway might therefore contribute to the perturbation of checkpoint activation in cancer cells.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 706 707 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
DNA damage checkpoints are signal transduction pathways that maintain the proper order of cell cycle events. When DNA is damaged or perturbed during replication, the cells respond by the activation of evolutionarily conserved signal transduction pathways that delay the progression of the cell cycle and induce repair of the damaged DNA. These signal transduction pathways include protein sensors that recognize aberrant DNA structures and activate kinases, thereby inducing phosphorylation cascades that ultimately lead to cell cycle arrest and DNA repair [1,2]. Failure of this cell cycle surveillance mechanism can cause genomic instability which eventually leads to the formation of cancer in mammals [3].
###end p 9
###begin p 10
###xml 40 66 40 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Schizosaccharomyces pombe </italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad </italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad1+</italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad3+</italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad9+</italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad17+</italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rad26+</italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hus1+</italic>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 611 612 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 613 615 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 911 913 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1297 1299 1293 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1570 1572 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1747 1749 1743 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1750 1752 1746 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1916 1918 1912 1914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2025 2027 2021 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2028 2030 2024 2026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2175 2177 2171 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 40 65 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
###xml 261 266 <span type="species:ncbi:4932">yeast</span>
hRad9 protein is the human homologue of Schizosaccharomyces pombe Rad9, a member of the checkpoint rad genes (rad1+, rad3+, rad9+, rad17+, rad26+, and hus1+) which are required for the S phase (DNA replication) and G2 (DNA mitosis) check points [4,5]. Like its yeast counterpart, hRad9 forms a ring-shaped, heterotrimeric complex with the hRad1 and hHus1 proteins [6,7]. Each member of hRad9-hRad1-hHus1 complex (also known as the 9-1-1 complex), shares sequence homology with proliferating cell nuclear antigen (PCNA), a homotrimer that encircles the DNA and tethers DNA polymerase delta during DNA synthesis [7-10]. PCNA is loaded onto DNA by the pentameric protein complex replication factor C (RFC) [11], which is composed of one large subunit and four smaller subunits. In a manner analogous to PCNA and RFC, 9-1-1 complex is loaded onto DNA by a complex between hRad17 and the four small subunits of RFC [12]. Since DNA damage induces hRad17-dependent association of 9-1-1 complex with chromatin, the 9-1-1 complex is believed to be involved in the direct recognition of DNA lesions during the initial stages of the checkpoint response; the 9-1-1 complex may thus be associated with chromatin following DNA damage to transduce signals for DNA damage-activated checkpoint signaling pathways [13]. In mammalian cells, the signal initiated by the sensors, two phosphatidylinositol 3-kinase-related kinases (PIKK), ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia mutated and Rad3-related (ATR), plays a central role in the checkpoint signaling pathways [14]. ATM and ATR are activated by downstream signaling proteins, genotoxins and phosphorylation including Chk1 and Chk2, two protein kinases that regulate checkpoint responses [15-17]. hRad9 is highly modified by phosphorylation in at specific points of the cell cycle after DNA damage, and it also plays a critical role in checkpoint signaling [18]. ATM-mediated phosphorylation at Ser-272 of hRad9 is required for IR-induced G1/S checkpoint activation [19,20]; Other phosphorylation sites in the C-terminal region are also essential for Chk1 activation following hydroxyurea (HU), IR, and UV treatment [20], although the exact function of hRad9 in cell cycle control has not yet been completely characterized.
###end p 10
###begin p 11
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 444 447 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 449 453 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45</italic>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAX</italic>
###xml 468 476 468 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF-BP3 </italic>
###xml 480 488 480 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYCLIN G</italic>
###xml 494 498 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1064 1068 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1236 1239 1236 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 1328 1332 1328 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
The tumor suppressor gene TP53 controls cell cycle checkpoints, apoptosis, and genomic stability [21]. A defect in the pathway, involving p53, is essential for the malignant progression of cancer [22]. When cells with wild-type TP53 are exposed to DNA-damaging agents, p53 is functionally activated, p53 protein level rises, and p53 binds to and transcriptionally activates the promoters of target genes [21,23,24]. These target genes include; P21, MDM2, GADD45, BAX, IGF-BP3 and CYCLIN G. The P21 gene product was originally identified, as a potential target for the p53 tumor suppressive activity (WAF1) [25]. It is either an inhibitor of the G1 cyclin-dependent kinases (Cip1) [26], or an inhibitor of DNA synthesis that is expressed during cellular senescence (SDI1) [27]. It is known that p21 is a major effector of the G1 cell cycle checkpoint. Therefore, p53 is a negative regulator of the cell cycle progression and it controls the transition from G1 to S phase of the cell cycle [28]. This report demonstrates that hRad9 plays a role in the modulation of P21 transcription by direct interaction with p53. Furthermore, the substitution of the phosphorylation sites on hRad9 to Ala resulted in an alteration of the regulation of P21. The present study supports the hypothesis that hRad9 plays a role in the modulation of P21 transcription, presumably via competition with p53, that involves its C-terminus, which would be essential for the cellular response to DNA damage.
###end p 11
###begin title 12
Results and discussion
###end title 12
###begin title 13
P21 is activated immediately after UV treatment
###end title 13
###begin p 14
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 917 921 917 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1221 1225 1221 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1293 1294 1293 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1354 1358 1354 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1449 1453 1449 1453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1644 1646 1644 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1679 1683 1679 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1801 1803 1801 1803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1935 1939 1935 1939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 1068 1073 <span type="species:ncbi:9606">human</span>
Several previous studies have shown that genotoxic stress induces the stabilization and transient accumulation of wild-type p53 protein in mammalian cells, leading to an increase of expression of p53 down-stream genes, including P21 [21,25]. Employing RT-PCR, the level of P21 mRNA expression of human embryonic kidney 293 cells was examined in these experiments. The level of P21 mRNA expression substantially increased at 30 min after UV irradiation and reached maximal levels at 1 hr thereafter. At that time, the mRNA levels were reduced but still detectable until 72 hr after UV exposure (Fig. 1A). Next, using the protein equivalent to each time points, a Western blotting analysis was performed to examine the time course of p21 protein expression. As shown in Figure 1B, a substantial increase of p21 was seen at 3, 12, and 24 hr following exposure to UV. These results indicate that the accumulation of both P21 transcript and p21 protein occurred, and G1/S checkpoint was activated after UV irradiation. Since 293 cells are immortalized by E1B, derived from human adenoviral proteins, and might be defective in p53 signaling, another MRC5 fibroblast cell line with wild-type p53 was examined, and observed that P21 mRNA increased about 3.3 fold after UV irradiation (Additional file 1), thus suggesting that exposure to UV leads an increase of P21 expression of both cell lines similarly under these conditions. This expression pattern of P21 mRNA and p21 protein suggests that the G1/S checkpoint is activated immediately after DNA damage, and inhibits damaged cells from progressing through the cell cycle and entering the S phase [29]. After the peak of activation, P21 transcription declined as observed in a recent report that indicated that p21 can be degraded during excision repair [30]. This suggests that more than the arrest of the cell cycle at G1 or a broad time period could thus be involved in the decrease of P21 mRNA and protein following UV exposure.
###end p 14
###begin title 15
The role of hRad9 in p53-dependent P21 activation through its C-terminus
###end title 15
###begin p 16
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 434 438 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1158 1160 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1171 1173 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1196 1200 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1207 1211 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1286 1288 1286 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1469 1471 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1508 1512 1508 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1556 1560 1556 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1775 1777 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1867 1869 1867 1869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1941 1943 1941 1943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2047 2049 2047 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2176 2178 2176 2178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2413 2417 2413 2417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 2427 2429 2427 2429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2512 2516 2512 2516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 2688 2690 2688 2690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2778 2780 2778 2780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2905 2909 2905 2909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 2928 2933 2928 2933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 2936 2938 2936 2938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2980 2984 2980 2984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3247 3251 3247 3251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
Utilizing the P21 promoter-luciferase reporter system, the functional aspect of regulation of P21 by hRad9 was assessed. Since phosphorylation of hRad9 is required for DNA damage checkpoint activation [20], the requirement of phosphorylation of hRad9 for P21 transcription was investigated using wild-type and the following phosphorylation-defective RAD9 mutants: 1) RAD9-S272A, with a substitution of Ser-272 with an Ala residue, 2) RAD9-9A, with substitutions of C-terminus phosphorylation sites including Ser-272, Ser-277, Ser-328, Ser-336, Ser-341, Ser-355, Ser-375, Ser-380, and Ser-387, with Ala, and 3) RAD9-8A, with substitutions of all C-terminus phosphorylation sites except for Ser-272, with Ala. Western blotting was performed to confirm the expression of the protein in wild-type and mutants,. Wild-type Rad9 was detectably expressed as a series of large proteins, suggesting the phosphorylated form(s) of hRad9 (Fig. 2A, lane 2) [18]. Rad9-S272A also expressed with a similar series of large proteins, presumably corresponding to different phosphorylated species of hRad9, with a gradient of phosphorylation excluding the Ser272 residue. (Fig. 2A, lane 3) [18]. The transfection of RAD9-8A or RAD9-9A resulted in a reduced phosphorylation compared to wild-type Rad9 (Fig. 2A, lanes 4 and 5, compared with lane 2). The results indicate that phosphorylation-defective mutants are substantially expressed and retain the capacity for reduced phosphorylation [18]. Afterward, the promoter region of P21 was fused to a luciferase reporter (WWP-Luc-P21 promoter) and it was cotransfected along with plasmids into cells as indicated. Background levels of expression were low, as demonstrated by a control transfection of empty vector and promoter-less pGL3-basic (Fig. 2B, column 1). By using the reporter vector, containing the p53-binding consensus sequence [31], the introduction of p53 expectedly induced luciferase activity (Fig. 2B, column 7). The introduction of the wild-type Rad9 also induced the positive luciferase activity (Fig. 2B, column 3), although not as intensively as p53. The co-expression of p53 and wild-type Rad9 induced luciferase activity (Fig. 2B, column 8) at an intermediate level in comparison to that seen when each protein is transfected independently. Considering these data, in association with the previous report of the potential transactivating property of hRad9 for the P21 promoter [32], these results support the concept that hRad9 can stimulate the transcription of P21 and it may modulate the p53 function. The luciferase activity was comparable among wild-type and phosphorylation-defective mutants following the plasmid introduction (Fig. 2B, columns 4 to 6, compared with 3), and was lower in the co-expression of mutants (Fig. 2B, columns 9 to 11, compared with 8), suggesting that the phosphorylation of hRad9 is involved in regulation of p53-dependent P21 transcription. Yin et al. [32] reported that wild-type hRad9 activates P21 transcription and that the co-expression of p53 and wild-type hRad9 results in the intermediate transcriptional activity by p53 or hRad9 alone, consistent with the present results. This suggests that phosphorylation may thus play a possible role in p53 dependent P21 transcription.
###end p 16
###begin title 17
Knock down of endogenous hRad9 increases the transcription of P21
###end title 17
###begin p 18
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 743 747 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 827 832 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 887 891 887 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1043 1049 1043 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 1095 1099 1095 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1191 1197 1191 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 1210 1214 1210 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1356 1360 1356 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2A</xref>
###xml 1543 1545 1543 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2B</xref>
###xml 1554 1558 1554 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 1647 1651 1647 1651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1703 1707 1703 1707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1753 1755 1753 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2C</xref>
###xml 1883 1887 1883 1887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1986 1988 1986 1988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 2068 2073 2068 2073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 2074 2076 2074 2076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 2259 2263 2259 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 2269 2274 2269 2274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 2403 2408 2403 2408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 2434 2438 2434 2438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 2635 2641 2635 2641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3A, 3B</xref>
###xml 2867 2869 2867 2869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 3339 3343 3339 3343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3398 3399 3398 3399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 3443 3447 3443 3447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3560 3564 3560 3564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3659 3661 3659 3661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 3662 3664 3662 3664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 3696 3700 3696 3700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3774 3778 3774 3778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 3928 3934 3928 3934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 4111 4113 4111 4113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 4114 4116 4114 4116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 4190 4192 4190 4192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 4218 4224 4218 4224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 4272 4281 4272 4281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 4282 4284 4282 4284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 4493 4497 4493 4497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
Endogenous hRad9 was knocked down using siRNA to address the role of hRad9 for the transcription of P21 in response to UV exposure. A Western blot analysis showed that siRNA treatment resulted in the reduction of endogenous p53 or hRad9 (Fig. 3A). In addition, hRad9 siRNA did not increase p53 protein compared to mock treatment (Fig. 3B). Using RT-PCR, the P21 mRNA level was determined. The knockdown of hRAD9 resulted in an increase in the level of P21 mRNA (Fig. 3C, column 3), whereas the knockdown of TP53 showed levels of P21 mRNA comparable to mock-treatment (Fig. 3C, column 2, compared with 1). This suggests that hRad9 plays a role in modulating P21 transactivation. After UV treatment, the mock-treated cells showed an increase of P21 mRNA (Fig. 3C, column 4), compared with UV (-) control, under these conditions. TP53 siRNA transfection resulted in an obvious reduction of P21 mRNA (Fig. 3C, column 5), thus suggesting that the effect of p53 reduction was appreciable after UV-induced damage under those conditions. In contrast, hRAD9 knockdown resulted in an apparent increase of P21 mRNA after UV exposure (Fig. 3C, column 6). The UV treatment was not simply additive to the hRAD9 knockdown in P21 transactivation, thus suggesting that the reduction of endogenous hRad9 resulted in a profound effect in UV damage-dependent and -independent P21 pathway. Furthermore, semi-quantitative RT-PCR and PCR-Southern blotting was performed to confirm the effect of Rad9 siRNA, and similar results were obtained (Additional files 2A and 2B). Using TP53-deficient MEFs, real time RT-PCR was used to confirm the effect of knockdown of Rad9 in P21 transcription, and this demonstrated an increase in P21 mRNA after knockdown of Rad9 (Additional file 2C), thus supporting the concept that Rad9 is not only an activator, but also a modulator in this pathway. The transactivation of P21 in the absence and reduction of the p53 and Rad9 may be due to transcription factors, such as sp1 [33]. In addition, a p53-deficient cell line TE-7, with transcriptionally inactive TP53 [34], was used to study the effect of the introduced hRad9 and p53 proteins under p53 negative background. TE-7 cells were transfected with wild-type or phosphorylation-defective mutant RAD9, and TP53 plasmids, and the expression of each protein was confirmed by Western blotting; the exogenous expression of wild-type and mutant RAD9 elicited the induction of P21 mRNA and its product, associated with Ser15 phosphorylation of transfected p53, whereas endogenous p53 and its phosphorylated form were undetectable without transgene introduction (Additional file 3A, 3B, and data not shown), thus suggesting that Rad9 may play a role in the p53-dependent p21 transactivation and Rad9-p53 might express a certain active function in p53 negative cancer cells, compatible with the previous report [32]. One might speculate that Rad9-p53 has a high affinity for the p21 promoter; rather than the induction of p21, the transfection could result in the reduction of p21 in endogenous p53-positive cells, and might stimulate p21 in p53-negative background. It also should be noted that numerous or uncharacterized, additional alterations might accumulate in cancer-derived cell lines. Taken together, the present data indicate that the transfection of hRad9 plays a role in P21 transcription, depending on the co-expressed p53 (Fig. 2), and the knockdown of hRad9 can stimulate P21 transactivation, thus suggesting that the protein level of hRad9 may be involved in modulation and regulation of P21 transactivation. Considering that other studies show that hRad9 accumulation after DNA damage [12,13] may enhance the modulation of P21 promoter activation, this supports the hypothesis that hRad9 may regulate P21 transcription in concert with p53, and that the reduction of hRad9 might elicit the checkpoint response. Recent studies with tumors indicate that the hRAD9 gene is located in a chromosomal region at 11q13. This genomic region is amplified and both mRNA and protein are frequently overexpressed in breast, lung, head and neck cancer [35,36]. This up-regulation is correlated with tumor size and local recurrence [35]. Furthermore, silencing hRAD9 by RNA interference inhibits cell proliferation in vitro [35]. These observations are consistent with the findings of the present study. Nevertheless, there is still insufficient data to determine whether hRad9 might be involved directly or indirectly in p53-dependent P21 activation. Therefore, the assessment of the direct association of hRad9-p53 is the next step.
###end p 18
###begin title 19
hRad9 associates with p53
###end title 19
###begin p 20
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 681 683 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 705 713 705 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 843 847 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1015 1020 1015 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 1198 1202 1198 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1210 1214 1210 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1223 1227 1223 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1262 1266 1262 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1273 1277 1273 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 1308 1310 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
The data reported above indicate that transfection of hRad9 modulates p53-dependent P21 promoter activation, and that knockdown of hRad9 stimulates p53-dependent P21 promoter activation. Therefore, the association of endogenous hRad9 with endogenous p53 was examined using immunoprecipitation. Endogenous hRad9 was co-immunoprecipitated with p53 from 293 cells (Fig. 4A). The hRad9-p53 association was then assessed in another MRC5 cells using immunoprecipitation and similar results were obtained (Additional file 4), thus suggesting that the association is not specific to the cell type. Considering these results, along with those of the pull-down assay of GST-fusion p53 with [35S] methionine-labeled in vitro-translated hRad9 protein (data not shown), the findings of the present study strongly suggests that hRad9 acts as a modulator of P21 transcription through a direct association with p53. To investigate whether phosphorylation of hRad9 affects the binding to p53, wild-type or phosphorylation-defective RAD9 mutants were transfected, and immunoprecipitation was performed. The results showed p53 to be associated with hRad9, in both the wild-type and phosphorylation-defective mutants (RAD9-S272A, RAD9-8A, and RAD9-9A). However the association with RAD9-8A or RAD9-9A was somewhat reduced (Fig. 4B). The data implicate the substantial association of p53 with intact hRad9, and that the hRad9 mutants might be altered in capacity for p53 binding, presumably due to conformational changes and affinity of complex, which would result the release of immunoprecipitated components after extensive washes.
###end p 20
###begin p 21
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
Previous studies have showed that p53 protein can be phosphorylated at Ser-15 within 1 hr after DNA damage [37]. A Western blot analysis indicated that Ser-15 of p53 was phosphorylated 5 min after UV treatment in the present experiments (Fig. 4C). The time course of this reaction was examined to determine whether the association of hRad9 and p53 might be altered after UV irradiation. Figure 4D demonstrates that the phosphorylation of p53 at Ser-15 in the immunoprecipitated components increased at 5 min and reached a maximal level at 6 hr after UV treatment, and declined, consistent with the Western blot findings in Figure 4C, whereas the total amount of Rad9-p53 interaction did not increase. In addition, other phosphorylation sites of p53, including Ser-6, Ser-9, Ser-20, Ser-37, Ser-46, and Ser-392 were also examined and they were phosphorylated temporally, regardless of the positive association of hRad9 with p53 over the time course, as observed Ser-15 (Fig. 4D, and data not shown). These results indicate that the binding of hRad9 and p53 is not significantly affected by phosphorylation, though it is possible that the modifications of the phosphorylation in these amino acid residues are not involved in the binding of the components.
###end p 21
###begin p 22
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The present immunoprecipitation study revealed hRad9 to be associated with p53, and the association was detected regardless of degree of phosphorylation of p53 and presumably of hRad9. A previous report also demonstrated that constitutive phosphorylation of hRad9 does not influence the stability of the 9-1-1 complex [20]. It is suggested that hRad9, as a complex with p53, may be involved in the transactivation of P21 and that the phosphorylations of hRad9 and p53 might modulate the transactivation activity of the complex. Whereas none of the phosphorylation sites of hRad9 targeted in the present study have been previously reported to be required for genotoxin-induced chromatin binding [20], the present data suggest that hRad9 phosphorylation might be involved in binding affinity for p53-consensus binding sites.
###end p 22
###begin title 23
Phosphorylation of hRad9 affects the preference of p53 for binding sites
###end title 23
###begin p 24
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 733 737 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 932 936 932 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 1255 1259 1255 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1437 1442 1437 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1713 1717 1713 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 2181 2183 2181 2183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 548 553 <span type="species:ncbi:9606">human</span>
The effects of alterations of the affinity of hRad9/p53 for p53-consensus binding sites of P21 promoter for chromatin remodeling after UV treatment were investigated. Previous studies show that hRad9 specifically binds to a p53-consensus DNA-binding sequence in the P21 promoter and regulates P21 at the transcriptional level [32]. A ChIP assay was used to evaluate whether the affinity of hRad9/p53 complex for p53 binding sites may increase after UV treatment, and whether the phosphorylation of hRad9 affects the affinity for binding sites. The human P21 promoter contains two p53-binding sites (Fig. 5A), and the treatment with 5-fluorouracil significantly enhances the recruitment of p53 protein to both upstream and downstream P21 promoter regions [33]. Therefore, each of the two p53-binding sites was observed. A ChIP assay with anti-p53 and anti-Rad9 antibodies showed that their binding to each of upstream and downstream P21 promoters was increased 15 to 30 min after UV treatment, whereas ChIP with anti-acethylated histone H4 antibody indicated that the acetylation around the P21 promoter was not altered significantly in the those conditions (Fig. 5B), thus suggesting that the association of p53 and hRad9, and its subsequent complex with P21 promoters is correlated with the regulation of transcription after UV exposure. Next, ChIP assays were performed with transfectants of the wild-type or phosphorylation-defective RAD9 plasmids. As shown in Figure 5C, hRad9 and p53 binding to the downstream site was inhibited by introduction of phosphorylation-defective mutants (as shown as asterisks). The association was increased after UV treatment, in all cases except for cells transfected with the RAD9-8A plasmid which showed a low affinity to the binding site. This suggests the possibility that systematic, scheduled or sequential phosphorylation of Ser residues in hRad9 might be necessary for efficient binding to p53-consensus DNA sequences. ChIP binding of hRad9 seems to be reduced slightly, compared to that of p53, which might be due to the specificity of the antibodies. Similar results with hRad9 and p53 were obtained at the upstream binding site (Fig. 5D). The present results suggest that the phosphorylation of the C-terminal region of hRad9 may play a role in modulation of the affinity for binding its consensus sites.
###end p 24
###begin p 25
###xml 200 202 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 228 230 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 292 294 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 428 432 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
Recent studies have demonstrated the multifunctional roles of hRad9 a DNA damage sensor in the 9-1-1 complex, a G2/M checkpoint via the phosphorylation of Chk1, in DNA repair via DNA polymerase beta [38] or flap endonuclease 1 [39], and in apoptosis via potential binding to Bcl-2 or Bcl-xL [40]. The present study, demonstrated the direct association of Rad9-p53 and the regulatory role of phosphorylation in the activation of P21 transcription, thus indicating that hRad9 is an important modulator, but not a unique player with a single function.
###end p 25
###begin title 26
Conclusion
###end title 26
###begin p 27
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
hRad9 has a complex role in response to DNA damage, acting not only as an activator but also as a modulator in P21 transcription and contributing to the regulation of genomic integrity. If hRad9 was regulated inaccurately, the P21 could not regulate the appropriate G1/S transition and replication, thus resulting in the occurrence of unscheduled replications after DNA damage. Such events can contribute to the accumulation of pathological conditions and genomic instability in carcinogenesis and tumor progression.
###end p 27
###begin title 28
Methods
###end title 28
###begin title 29
Cell culture
###end title 29
###begin p 30
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 192 195 <span type="species:ncbi:9913">cow</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 334 340 <span type="species:ncbi:10090">Murine</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
Human embryonic kidney 293 cells, immortalized by E1B protein, derived from a part of the human adenovirus, and MRC5 fibroblasts with wild-type p53 status were cultured in DMEM with 10% fetal cow serum (FCS). TE-7 cell line derived from human esophageal cancers, which p53 is inactivated by transcriptional repression [34], was used. Murine embryonic fibroblast (MEF) cell lines were obtained from TP53-deficient and control wild-type mice (Jackson Laboratory). After pairs of mice were mated, MEFs obtained from sub-cutaneous tissue of embryos at 13.5 post-coital days were grown in DMEM medium with 20% FBS. Cells were transfected with 3 ug of expression plasmid of siRNA to inhibit Rad9 (pBAsi-mU6 plasmid, TAKARA, sequence in Table 1), selected in medium with 1 ug/ml puromycin. For exposure to UV, 60% to 70% confluent monolayer cells were washed and irradiated with UVC emitted by germicidal lamps (GL-15; NIPPO Electronic). Irradiation dose was measured with a digital UV-C densitometer (UCV-254; Custom). Control cells were taken into the UV exposure source but were not irradiated.
###end p 30
###begin title 31
Antibodies and plasmids
###end title 31
###begin p 32
The following antibodies were used: anti-Rad9 (Alexis), anti-p53 (BD Transduction Laboratories), anti-acetylated histone H4 (Upstate Biotechnology), anti-FLAG (Sigma-Aldrich), and anti-phosphorylated p53 (Ser-15) antibody (Cell Signaling Technology).
###end p 32
###begin p 33
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
We used the wild-type RAD9 plasmid and the phosphorylation-defective RAD9 mutants, kindly given from Dr. L. M. Karnitz [20]. To construct FLAG-tagged RAD9 expression plasmids, the DNAs were amplified by the PCR method with the advantage Clontaq system with high fidelity (Clontech) according to the manufacture's instruction, by using wild-type and RAD9 mutant vectors as templates and a set of primers (Table 1). The amplified products were separated by the electrophoresis, cut and purified with gel purification kit (Qiagen). After digestion with NotI and XbaI, the samples were ligated to the cloning site of pcDNA3.1-FLAG vector. WWP-Luc-P21 promoter vector, kindly given from Dr. B. Vogelstein [25], pcDNA-TP53 expression plasmid, kindly given from Dr. J. Yokota [41].
###end p 33
###begin title 34
Transfection
###end title 34
###begin p 35
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Plasmids were transfected with LipofectAMINE2000 according to manufacturer's instructions (Invitrogen). Double-stranded siRNAs for hRAD9 and TP53 (Santa Cruz Biotechnology) were transfected twice 24 h apart using TransIT-TKO transfection reagent (Mirus).
###end p 35
###begin title 36
Reverse transcription (RT)-PCR and real time PCR
###end title 36
###begin p 37
###xml 279 280 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 281 283 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 284 286 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 318 321 317 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21</italic>
###xml 472 477 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH</italic>
###xml 985 987 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1206 1208 1157 1159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1224 1228 1175 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1231 1237 1182 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
###xml 1358 1362 1309 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
RNA was extracted using ISOGEN protocol (Nippon Gene). First-strand cDNA was prepared from total RNA (5 mug) and oligo (dT) using the Superscript First-Strand Synthesis System (Invitrogen). The synthesized cDNA was amplified by PCR. The oligonucleotides used were shown in Table 1[42,43]. The PCR conditions were: for P21, an initial denaturation at 94degreesC for 1 min, followed by 37 cycles of 94degreesC for 8 sec, 53degreesC for 30 sec, and 72degreesC for 1 min; for G3PDH, the denaturation at 94degreesC for 1 min, followed by 28 cycles of 94degreesC for 10 sec, 60degreesC for 15 sec, and 72degreesC for 1 min. PCR products were separated by electrophoresis and visualized by ethidium bromide staining. The intensity of each band corresponding to PCR was quantified by densitometry analysis (Quantity One, BIO-RAD). The negative control without RTase showed no amplifications. Each experiment was repeated at least thrice. PCR-Southern blot analysis was performed as described [44], with minor modifications. Briefly, after four different cycles (24, 28, 32 and 36) of PCR, reactions (20 ul) in separate tubes were subjected to electrophoresis, transferred to nylon filter and were hybridized with [32P] dCTP-labeled P21 or G3PDH probe, which was amplified by RT-PCR. After washes, filter was exposed on x-ray film. For Real time RT-PCR assessment of P21 expression, total RNA was extracted and cDNA was synthesized. Primers and TaqMan probe were used for amplification and assessment according to the manufacture's instruction (Mm00432448_m1, Applied Biosystems).
###end p 37
###begin title 38
Protein study
###end title 38
###begin p 39
For Western blotting, cells were extracted with lysis buffer [20 mM Tris-Hcl (PH 7.4), 1% Triton x 100, 10% glycerol, and 0.1 mM PMSF]. The cleared extracts were resolved by SDS-PAGE, and transferred to polyvinylidene difluoride membrane. Immunoblotting was performed by standards methods and signal was detected enhanced chemiluminescence system (ECL, Amarsham Biosciences). The intensity of each band was quantified by densitometry analysis (Quantity One, BIO-RAD). For immunoprecipitation (IP), cells were harvested with IP-lysis buffer [25 mM Tris-HCl (PH 7.5), 0.2% NP40, 250 mM NaCl, and 1 mM EDTA] and 500 mug of cell lysates, after being precleared with protein G-Sepharose beads, were incubated with 3 mug of specific antibody overnight. Antigen-antibody complex was immobilized on protein G-Sepharose beads, and washed five times in lysis buffer. Bound proteins were eluted by boiling and subjected to SDS-PAGE and immunoblotting.
###end p 39
###begin title 40
Promoter study
###end title 40
###begin p 41
###xml 508 516 508 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Firefly </italic>
###xml 519 527 519 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renille </italic>
###xml 716 718 716 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1495 1499 1477 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1542 1543 1524 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1544 1546 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1489 1494 <span type="species:ncbi:9606">human</span>
For luciferase reporter assay, transfected cells were cultured in a complete growth medium for 24 h and harvested, performed according to the manufacture's instruction (Promega). Each plasmids including empty expression vector were transfected with the same amounts (60 ng). Luciferase activity was measured on a Fluoroskan Ascent FL Luminometer (Thermo Labsystems Oy). As the internal control, each sample was co-transfected with pRL-TK, and the relative luciferase activity was figured out as the ratio of Firefly to Renille to adjust the tansfection rates. Each experiment was repeated at least thrice. Chromatin immunoprecipitation (ChIP) assay was performed using the Upstate Biotechnology kit. Briefly, ~1 x 106 cells were cross-linked with 1% formaldehyde, resuspended in 200 muL of SDS-lysis buffer, and sonicated to disrupt chromatin at an average length of 200 to 1,000 bp. After centrifugation, 20 muL of each supernatant were heated at 65degreesC for 4 h after the addition of 1 muL of 5 M NaCl, which was used as an input. The rest of the supernatant was added to 300 muL of ChIP dilution buffer containing 1 mug of either anti-Rad9 or anti-p53 antibody. After incubation at 4degreesC for 16 h, the immunoprecipitates were washed, eluted, heat treated, and digested with proteinase K. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. We used one tenth (2 muL) of the final suspension for PCR using primers corresponding to different regions of the human P21 promoter. Primers used were shown in Table 1[33].
###end p 41
###begin title 42
Authors' contributions
###end title 42
###begin p 43
Ka. I. performed experiments and participated in experimental design and writing of manuscript. H. I. conceived the study, reviewed and analyzed all data and drafted the manuscript. K. M. and M. M. performed quantitative RT-PCR. M. K. and K. Y. prepared the experimental materials and conceived the study. Y. M., H. N., Y. F. and Ke. I. participated in experimental design and writing of manuscript. All authors read and approved the final manuscript.
###end p 43
###begin title 44
Supplementary Material
###end title 44
###begin title 45
Additional file 1
###end title 45
###begin p 46
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UV-induced effect on the expression of <italic>P21 </italic>mRNA in MRC5 cell line</bold>
###xml 106 108 106 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
UV-induced effect on the expression of P21 mRNA in MRC5 cell line. MRC5 cells were exposed to UV at 20 J/m2 and harvested 0, 1, and 3 hr after the treatment as indicated. Total RNA was extracted and RT-PCR was performed. The ratio of P21 mRNA to G3PDH is shown. Data represent the means +/- SD of three independent experiments.
###end p 46
###begin p 47
Click here for file
###end p 47
###begin title 48
Additional file 2
###end title 48
###begin p 49
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alteration of P21 mRNA expression in the knockdown experiment by <italic>hRAD9 </italic>or <italic>TP53 </italic>siRNA</bold>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 414 420 414 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
###xml 586 590 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 656 660 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
Alteration of P21 mRNA expression in the knockdown experiment by hRAD9 or TP53 siRNA. (A) Semi-quantitative RT-PCR after siRNA knockdown of hRad9 and p53. Cells were treated with hRAD9 (siRad9) or TP53 siRNA (siP53) and subjected to UV exposure. Cells were harvested and RNAs were extracted for RT-PCR with P21 primers. Samples were collected during each PCR cycle as indicated. The relative amount of P21 mRNA to G3PDH mRNA was measured with densitometry, and the data are shown. Data represent the means +/- SD of three independent experiments. (B) Semi-quantitative determination of P21 mRNA using PCR-Southern blot analysis. (C) Real-time RT-PCR using TP53-deficient MEFs after siRNA knockdown of hRad9. Data represent the means +/- SD of three independent experiments.
###end p 49
###begin p 50
Click here for file
###end p 50
###begin title 51
Additional file 3
###end title 51
###begin p 52
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UV-induced effect on the expression of <italic>P21 </italic>mRNA in TE-7 cell line</bold>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 622 628 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
UV-induced effect on the expression of P21 mRNA in TE-7 cell line. (A) Western blots of lysates from TE-7 transfectants of wild-type RAD9, RAD9-9A mutant and TP53 plasmid, as indicated. Lysates were analyzed by Western blotting, probed with anti-p53, anti-phosphorylated p53 (Ser15), anti-p21 or anti-actin antibody. (B) Alteration of P21 mRNA expression in the transfection with wild-type RAD9, RAD9-9A mutant and TP53 plasmid. Cells were transfected with plasmids as indicated and subjected to UV exposure. The cells were harvested and RNAs were extracted for RT-PCR with P21 primers. The relative amount of P21 mRNA to G3PDH mRNA is shown. Data represent the means +/- SD of three independent experiments.
###end p 52
###begin p 53
Click here for file
###end p 53
###begin title 54
Additional file 4
###end title 54
###begin p 55
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interaction between hRad9 and p53 in MRC5</bold>
Interaction between hRad9 and p53 in MRC5. Immunoprecipitation and a Western blot analysis were performed using cell lysate of MRC5. Anti-c-kit antibody was used as a negative control.
###end p 55
###begin p 56
Click here for file
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 401 405 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 304 308 <span type="species:ncbi:162683">Mayo</span>
We thank Bert Vogelstein (The Johns Hopkins Oncology Center, Baltimore, USA) for giving WWP-Luc-P21 promoter plasmid kindly, Jun Yokota (National cancer Center Research Institute, Tokyo, Japan) for giving TP53 plasmid kindly, and Larry M. Karnitz (Developmental Oncology Research and Radiation Oncology, Mayo Clinic and Foundation, Rochester, Minnesota, USA) for giving RAD9 plasmids (wild-type RAD9, RAD9-S272A, RAD9-8A, RAD9-9A) kindly. We thank Larry M. Karnitz and Jun Yokota for critical reading the manuscript and helpful suggestions.
###end p 58
###begin p 59
This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and The Research Award to JMS Graduate Student.
###end p 59
###begin article-title 60
DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
###end article-title 60
###begin article-title 61
Cell cycle checkpoints: preventing an identity crisis
###end article-title 61
###begin article-title 62
Genetic instability in colorectal cancers
###end article-title 62
###begin article-title 63
###xml 37 62 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
DNA structure checkpoint pathways in Schizosaccharomyces pombe
###end article-title 63
###begin article-title 64
###xml 50 55 <span type="species:ncbi:4932">yeast</span>
Mitotic DNA damage and replication checkpoints in yeast
###end article-title 64
###begin article-title 65
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein that forms complexes with hRAD1 and hHUS1
###end article-title 65
###begin article-title 66
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 18 43 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
Human homologs of Schizosaccharomyces pombe rad1, hus1, and rad9 form a DNA damage-responsive protein complex
###end article-title 66
###begin article-title 67
Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex
###end article-title 67
###begin article-title 68
###xml 20 45 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
Characterization of Schizosaccharomyces pombe Hus1: a PCNA-related protein that associates with Rad1 and Rad9
###end article-title 68
###begin article-title 69
A sliding clamp model for the Rad1 family of cell cycle checkpoint proteins
###end article-title 69
###begin article-title 70
The DNA replication fork in eukaryotic cells
###end article-title 70
###begin article-title 71
###xml 15 20 <span type="species:ncbi:9606">human</span>
Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro
###end article-title 71
###begin article-title 72
###xml 17 22 <span type="species:ncbi:9606">human</span>
Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage
###end article-title 72
###begin article-title 73
Cell cycle checkpoint signaling through the ATM and ATR kinases
###end article-title 73
###begin article-title 74
CHK2 kinase--a busy messenger
###end article-title 74
###begin article-title 75
Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways
###end article-title 75
###begin article-title 76
Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor
###end article-title 76
###begin article-title 77
A role for the phosphorylation of hRad9 in checkpoint signaling
###end article-title 77
###begin article-title 78
###xml 33 38 <span type="species:ncbi:9606">human</span>
ATM-dependent phosphorylation of human Rad9 is required for ionizing radiation-induced checkpoint activation
###end article-title 78
###begin article-title 79
###xml 19 24 <span type="species:ncbi:9606">human</span>
Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling
###end article-title 79
###begin article-title 80
###xml 18 28 <span type="species:ncbi:111938">gatekeeper</span>
p53, the cellular gatekeeper for growth and division
###end article-title 80
###begin article-title 81
###xml 24 29 <span type="species:ncbi:9606">human</span>
Molecular footprints of human lung cancer progression
###end article-title 81
###begin article-title 82
Definition of a consensus binding site for p53
###end article-title 82
###begin article-title 83
Identification of p53 as a sequence-specific DNA-binding protein
###end article-title 83
###begin article-title 84
WAF1, a potential mediator of p53 tumor suppression
###end article-title 84
###begin article-title 85
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
###end article-title 85
###begin article-title 86
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
###end article-title 86
###begin article-title 87
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
###end article-title 87
###begin article-title 88
hRad9 rapidly binds DNA containing double-strand breaks and is required for damage-dependent topoisomerase II beta binding protein 1 focus formation
###end article-title 88
###begin article-title 89
UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair
###end article-title 89
###begin article-title 90
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues
###end article-title 90
###begin article-title 91
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21
###end article-title 91
###begin article-title 92
Inhibition of p53-mediated transcriptional responses by mithramycin A
###end article-title 92
###begin article-title 93
###xml 59 64 <span type="species:ncbi:9606">human</span>
Inactivation of the p53 protein in cell lines derived from human esophageal cancers
###end article-title 93
###begin article-title 94
The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer
###end article-title 94
###begin article-title 95
Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells
###end article-title 95
###begin article-title 96
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
###end article-title 96
###begin article-title 97
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA polymerase beta and increases its DNA substrate utilisation efficiency: implications for DNA repair
###end article-title 97
###begin article-title 98
The two DNA clamps Rad9/Rad1/Hus1 complex and proliferating cell nuclear antigen differentially regulate flap endonuclease 1 activity
###end article-title 98
###begin article-title 99
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 19 27 <span type="species:ncbi:4896">S. pombe</span>
Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis
###end article-title 99
###begin article-title 100
###xml 70 75 <span type="species:ncbi:9606">human</span>
Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines
###end article-title 100
###begin article-title 101
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Genomic analysis of differentially expressed genes in liver and biliary epithelial cells of patients with primary biliary cirrhosis
###end article-title 101
###begin article-title 102
###xml 53 58 <span type="species:ncbi:9606">human</span>
Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent
###end article-title 102
###begin article-title 103
Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity
###end article-title 103
###begin title 104
Figures and Tables
###end title 104
###begin p 105
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UV-induced effect on the expression of <italic>P21 </italic>mRNA and p21 protein</bold>
###xml 103 105 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 249 253 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 314 318 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 326 332 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
UV-induced effect on the expression of P21 mRNA and p21 protein. 293 cells were exposed to UV at 20 J/m2 and harvested 0 to 72 hr after treatment as indicated. Data represent the means +/- SD of three independent experiments. (A) The time course of P21 mRNA expression. RNA was extracted for RT-PCR. The ratios of P21 mRNA to G3PDH mRNA were measured with densitometry. (B) The time course of p21 protein expression. Cell lysates were extracted and separated by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with anti-p21 antibody. The signal intensity of the Western blotting is shown.
###end p 105
###begin p 106
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of wild-type and phosphorylation-defective hRad9 mutants expression on <italic>P21 </italic>transactivation</bold>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 273 276 273 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 563 571 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Firefly </italic>
###xml 574 581 574 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renille</italic>
Effect of wild-type and phosphorylation-defective hRad9 mutants expression on P21 transactivation. (A) Western blots of lysates from 293 transfectants of wild-type or phosphorylation-defective RAD9 mutants. Lysates were analyzed by Western blotting, probed with anti-Rad9 (top), anti-FLAG (middle), or anti-actin (bottom) antibody. (B) P21 transcription assay with wild-type and phosphorylation-defective RAD9. mutants using P21 promoter-luciferase reporter system. After transfection into 293 cells, the relative luciferase activities are shown as the ratios of Firefly to Renille. Data represent the means +/- SD of four independent experiments.
###end p 106
###begin p 107
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Knockdown experiment of hRad9 and p53 using siRNAs</bold>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 343 348 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hRAD9 </italic>
###xml 495 500 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G3PDH </italic>
Knockdown experiment of hRad9 and p53 using siRNAs. (A) hRad9 and p53 expression after transfection with hRAD9 (siRad9) or TP53 siRNA (siP53). The signals of immunoblots were measured with a densitometer, and the ratios of hRad9 or p53 to actin control were depicted in the figure. (B) p53 expression after transfection with hRAD9 (siRad9) or TP53 siRNA (siP53). (C) Alteration of P21 mRNA expression in the knockdown experiment by hRAD9 or TP53 siRNA. Cells were treated with hRAD9 (siRad9) or TP53 siRNA (siP53) and subjected to UV exposure or mock treatment. The cells were harvested and RNAs were extracted for RT-PCR with P21 primers. The relative amount of P21 mRNA to G3PDH mRNA is shown. Data represent the means +/- SD of three independent experiments.
###end p 107
###begin p 108
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interaction between hRad9 and p53</bold>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 472 478 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 669 671 669 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1066 1068 1064 1066 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
Interaction between hRad9 and p53. (A) Endogenous association of hRad9 and p53. Immunoprecipitation and Western blot analysis were performed using lysates of 293 cells. Anti-c-kit antibody was used as a negative control. (B) Immunoprecipitation using cell lysates of 293 transfectants with FLAG-tagged wild-type or phosphorylation-defective RAD9 plasmids. Each cell lysate was immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-p53 (top) or anti-FLAG (bottom) antibody. HC, IgG heavy chain of the anti-FLAG antibody. (C) The time course experiment for the accumulation of phosphorylated p53 at Ser-15 after UV. 293 cells were exposed to UV at 20 J/m2 and harvested 0 to 72 hr after treatment as indicated. A Western blot analysis was performed using anti-phosphorylated p53 (Ser-15) antibody. Relative expression of phosphorylated p53 to whole p53 is shown. Data represent the means +/- SD of three independent experiments. (D) The time course experiment of hRad9/p53 complex formation after exposure to UV. 293 cells were exposed to UV at 20 J/m2 and harvested 0 to 72 hr after treatment. Top, immunoprecipitation with anti-p53 antibody and Western blot analysis using anti-Rad9 antibody; middle, immunoprecipitation with anti-Rad9 antibody and Western blot with anti-p53 antibody; bottom, immunoprecipitation with anti-Rad9 antibody and Western blot with anti-phosphorylated p53 (Ser-15) antibody.
###end p 108
###begin p 109
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UV exposure-dependent increase of the hRad9 association to the p53-binding site in the <italic>P21 </italic>promoter</bold>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 347 351 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 369 374 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 635 639 635 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD9 </italic>
###xml 830 834 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 858 863 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1069 1073 1067 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
###xml 1131 1135 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1159 1164 1157 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1170 1174 1168 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P21 </italic>
UV exposure-dependent increase of the hRad9 association to the p53-binding site in the P21 promoter. (A) Schematic representation of the P21 promoter showing the location of the oligonucleotide primer sets, utilized in the ChIP assays. (B) ChIP assay with anti-p53 antibody, anti-acetylated histone H4 antibody or anti-Rad9 antibody for upstream (left) and downstream (right) P21 promoter sites. 293 cells were harvested with or without exposure to UV. ChIP assays were performed using anti-p53 (p53) or anti-acetylated histone H4 antibody (Ac-H4). Anti-c-kit antibody was used as a negative control. (C) ChIP assay for the downstream P21 promoter site. 293 cells were transfected with wild-type or phosphorylation-defective RAD9 plasmids, and harvested before and after exposure to UV. ChIP assays were performed with anti-Rad9 (left) or anti-p53 antibody (right). The relative intensity of signals of immunoprecipitated DNA to input DNA was measured with densitometry. Data represent the means +/- SD of three independent experiments. (D) ChIP assay for the upstream P21 promoter site. ChIP assays were performed with anti-Rad9 (left) or anti-p53 antibody (right) for P21 promoter upstream-binding site. Data represent the means +/- SD of three independent experiments.
###end p 109
###begin p 110
Primers and Probes for Each Experiments
###end p 110

